Asset Details
Do you wish to reserve the book?
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Do you wish to request the book?
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
2017
Overview
This open-label, randomized trial assessed the safety of uninterrupted dabigatran versus warfarin in 635 patients undergoing ablation for atrial fibrillation. The incidence of major bleeding events was significantly lower with dabigatran than with warfarin (1.6% vs. 6.9%).
Catheter ablation of atrial fibrillation is a well-established treatment for symptomatic atrial fibrillation. Guidelines have incorporated catheter ablation of symptomatic atrial fibrillation as a class 1 or 2 indication, depending on previous antiarrhythmic treatment and type of atrial fibrillation.
1
–
3
The most important complications associated with ablation of atrial fibrillation are periprocedural stroke or transient ischemic attack (TIA) and cardiac tamponade.
3
Systemic anticoagulation before, during, and after ablation is important in reducing the risk of periprocedural cerebrovascular events.
3
To minimize these risks, heparin should be administered during ablation to maintain an activated clotting time of more than 300 seconds. However, . . .
Publisher
Massachusetts Medical Society
Subject
/ Aged
/ Anticoagulants - administration & dosage
/ Anticoagulants - adverse effects
/ Atrial Fibrillation - drug therapy
/ Atrial Fibrillation - surgery
/ Bleeding
/ Dabigatran - administration & dosage
/ Dabigatran - adverse effects
/ Female
/ Hematoma
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Patients
/ Postoperative Complications - chemically induced
/ Postoperative Complications - epidemiology
/ Stroke
/ Stroke - prevention & control
/ Warfarin
